Abstract | BACKGROUND AND OBJECTIVES: METHODS: RESULTS: The 1-year survival for patients treated with radiotherapy alone was 29%. The 1-, 2-, and 3-year survivals for patients treated with the adjuvant chemotherapy after radiotherapy were 50, 40, and 30%, respectively (P = 0.0069, log-rank test). The elevation of tumor markers was delayed (P = 0.0346) and local control rate was improved (P = 0.0475) in patients with chemotherapy. Multivariate analysis demonstrated that the adjuvant chemotherapy with 5'-DFUR was a significant independent prognostic factor as well as tumor size. CONCLUSIONS:
|
Authors | K Tsuruta, A Okamoto, N Egawa, T Kamisawa, K Karasawa, T Takahashi |
Journal | Journal of surgical oncology
(J Surg Oncol)
Vol. 78
Issue 3
Pg. 202-7
(Nov 2001)
ISSN: 0022-4790 [Print] United States |
PMID | 11745808
(Publication Type: Journal Article, Review)
|
Copyright | Copyright 2001 Wiley-Liss, Inc. |
Chemical References |
- Antimetabolites, Antineoplastic
- Floxuridine
- doxifluridine
|
Topics |
- Administration, Oral
- Aged
- Antimetabolites, Antineoplastic
(administration & dosage)
- Chemotherapy, Adjuvant
- Drug Administration Schedule
- Female
- Floxuridine
(administration & dosage)
- Humans
- Male
- Middle Aged
- Pancreatic Neoplasms
(drug therapy, radiotherapy)
- Prognosis
- Radiotherapy Dosage
- Retrospective Studies
- Survivors
|